Design Therapeutics (DSGN)
NASDAQ:DSGN
US Market
Holding DSGN?
Track your performance easily

Design Therapeutics (DSGN) Income Statement

82 Followers

Design Therapeutics Income Statement

Last quarter (Q3 2024), Design Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Design Therapeutics's net income was $-13.04M. See Design Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 834.00K
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 60.81M$ 78.19M$ 67.59M$ 35.83M$ 8.33M$ 2.74M
Operating Income
$ -60.81M$ -78.19M$ -67.59M$ -35.83M$ -8.33M$ -1.91M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ 9.63M$ 11.33M$ 4.29M$ -298.00K$ 50.00K$ -139.00K
Pretax Income
$ -47.78M$ -66.86M$ -63.31M$ -35.53M$ -8.28M$ -2.05M
Tax Provision
$ -37.00K$ -37.00K$ -200.00K$ -9.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -47.78M$ -66.86M$ -63.31M$ -35.53M$ -8.28M$ -2.05M
Basic EPS
$ -0.84$ -1.19$ -1.14$ -0.77$ -0.30$ -0.08
Diluted EPS
$ -0.84$ -1.19$ -1.14$ -0.77$ -0.30$ -0.08
Basic Average Shares
$ 225.76M$ 55.98M$ 55.71M$ 45.94M$ 27.19M$ 27.19M
Diluted Average Shares
$ 225.76M$ 55.98M$ 55.71M$ 45.94M$ 27.19M$ 27.19M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 60.81M$ 78.19M$ 67.59M$ 35.83M$ 8.33M$ 2.74M
Net Income From Continuing And Discontinued Operation
$ -47.78M$ -66.86M$ -63.31M$ -35.53M$ -8.28M$ -2.05M
Normalized Income
$ -24.58M---$ -8.28M$ -2.05M
Interest Expense
------
EBIT
$ -54.35M$ -78.19M$ -67.59M$ -35.53M$ -8.33M$ -1.91M
EBITDA
$ -52.03M$ -77.65M$ -67.19M$ -35.46M$ -8.32M$ -1.91M
Currency in USD

Design Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis